High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

[1]  Lisa E. Gralinski,et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.

[2]  R. Owens,et al.  Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 , 2020, Nature Structural & Molecular Biology.

[3]  D. Fremont,et al.  Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 , 2020, Cell Host & Microbe.

[4]  M. Nussenzweig,et al.  Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.

[5]  Tokiko Watanabe,et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[6]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[7]  Z. Rao,et al.  Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody , 2020, Science.

[8]  Kwok-Hung Chan,et al.  Long SARS-CoV-2 nucleocapsid sequences in blood monocytes collected soon after hospital admission , 2020, bioRxiv.

[9]  M. Nussenzweig,et al.  Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.

[10]  D. Fremont,et al.  Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. , 2020, SSRN.

[11]  Lisa E. Gralinski,et al.  SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , 2020, Cell.

[12]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[13]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[14]  M. Mandal,et al.  Mutations in Spike Protein of SARS-CoV-2 Modulate Receptor Binding, Membrane Fusion and Immunogenicity: An Insight into Viral Tropism and Pathogenesis of COVID-19 , 2020 .

[15]  X. Xie,et al.  Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.

[16]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[17]  Lisa E. Gralinski,et al.  Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models , 2020 .

[18]  Lisa E. Gralinski,et al.  Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody , 2020, bioRxiv.

[19]  Lu Lu,et al.  Identification of Human Single-Domain Antibodies against SARS-CoV-2 , 2020, Cell Host & Microbe.

[20]  H. Yen,et al.  Peer Review File Manuscript Title: Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020 .

[21]  Lisa E. Gralinski,et al.  A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures , 2020, bioRxiv.

[22]  F. Gao,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[23]  Y. Shoenfeld,et al.  Convalescent plasma in Covid-19: Possible mechanisms of action , 2020, Autoimmunity Reviews.

[24]  Hongbing Shen,et al.  Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection , 2020, bioRxiv.

[25]  Hongbing Shen,et al.  Isolating multiple formats of human monoclonal neutralizing antibodies against SARS-CoV-2 by in vitro site-directed antibody screening , 2020 .

[26]  S. Zhang,et al.  Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig , 2020, Nature Communications.

[27]  Q. Jin,et al.  Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain , 2020, Nature Communications.

[28]  Wenhui Li,et al.  The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement , 2020, bioRxiv.

[29]  I. Wilson,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[30]  F. Krammer,et al.  SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.

[31]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[32]  N. Callewaert,et al.  Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[33]  K. To,et al.  Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Arturo Casadevall,et al.  The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.

[35]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[36]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[37]  Xiang Li,et al.  Bat origin of a new human coronavirus: there and back again , 2020, Science China Life Sciences.

[38]  D. Dimitrov,et al.  Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold , 2020, mAbs.

[39]  Zhènglì Shí,et al.  An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies , 2020, Emerging microbes & infections.

[40]  Zhènglì Shí,et al.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, bioRxiv.

[41]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[42]  S. Raunser,et al.  SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM , 2019, Communications Biology.

[43]  Z. Sauna,et al.  Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity , 2019, The AAPS Journal.

[44]  David F. Tucker,et al.  Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles , 2018, Proceedings of the National Academy of Sciences.

[45]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[46]  J. Nilvebrant,et al.  Engineered Autonomous Human Variable Domains. , 2017, Current pharmaceutical design.

[47]  Trushar R. Patel,et al.  Dynamic light scattering: a practical guide and applications in biomedical sciences , 2016, Biophysical Reviews.

[48]  Yang Feng,et al.  Antibody Aggregation: Insights from Sequence and Structure , 2016, Antibodies.

[49]  D. Dimitrov,et al.  Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection , 2016, Scientific Reports.

[50]  Krishna Shankara Narayanan,et al.  Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus , 2016, Human vaccines & immunotherapeutics.

[51]  R. Kontermann,et al.  Pharmacokinetic properties of IgG and various Fc fusion proteins in mice , 2016, mAbs.

[52]  C. Palomo,et al.  Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection , 2015, Antimicrobial Agents and Chemotherapy.

[53]  Amanda C. Freise,et al.  In vivo imaging with antibodies and engineered fragments. , 2015, Molecular immunology.

[54]  M. Piechaczyk,et al.  Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents? , 2015, Trends in Microbiology.

[55]  B. Haynes,et al.  Eliminating antibody polyreactivity through addition of N‐linked glycosylation , 2015, Protein science : a publication of the Protein Society.

[56]  M. Howarth,et al.  Site-specific biotinylation of purified proteins using BirA. , 2015, Methods in molecular biology.

[57]  S. Cowley,et al.  Recombinant Protein Expression for Structural Biology in HEK 293F Suspension Cells: A Novel and Accessible Approach , 2014, Journal of visualized experiments : JoVE.

[58]  D. Dimitrov,et al.  Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases , 2014, mAbs.

[59]  D. Dimitrov,et al.  Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies , 2014, Journal of Virology.

[60]  Shibo Jiang,et al.  A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein , 2014, Journal of Virology.

[61]  Shibo Jiang,et al.  A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines , 2013, PloS one.

[62]  Vineet D. Menachery,et al.  Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus , 2013, Proceedings of the National Academy of Sciences.

[63]  Shibo Jiang,et al.  A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV , 2013, Virology Journal.

[64]  Sjors H.W. Scheres,et al.  RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.

[65]  A. Nelson.  Antibody fragments , 2010, mAbs.

[66]  D. Dimitrov,et al.  Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers , 2008, Proceedings of the National Academy of Sciences.

[67]  D. Dimitrov,et al.  Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. , 2008, Journal of molecular biology.

[68]  H. de Haard,et al.  Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.

[69]  D. Dimitrov,et al.  Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies , 2007, Proceedings of the National Academy of Sciences.

[70]  Xiaodong Cen,et al.  Construction of a large phage display antibody library by in vitro package and in vivo recombination , 2006, Applied Microbiology and Biotechnology.

[71]  P. Maes,et al.  Growth kinetics of SARS-coronavirus in Vero E6 cells , 2005, Biochemical and Biophysical Research Communications.

[72]  Baoan Yang,et al.  Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines , 2005, Virology.

[73]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[74]  D. Dimitrov,et al.  The SARS-CoV S glycoprotein: expression and functional characterization , 2003, Biochemical and Biophysical Research Communications.

[75]  Ralph S. Baric,et al.  Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Tom Misteli,et al.  In vivo imaging. , 2003, Methods.

[77]  Q. Sattentau,et al.  Occupancy and mechanism in antibody-mediated neutralization of animal viruses. , 2002, The Journal of general virology.

[78]  L. Wyns,et al.  Camel heavy‐chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen‐binding repertoire , 2000, The EMBO journal.

[79]  T. Saito,et al.  FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. , 1996, Blood.

[80]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.